AbbVie Dividends and Buybacks
Dividend criteria checks 4/6
AbbVie is a dividend paying company with a current yield of 3.04%. Next payment date is on 17th February, 2026 with an ex-dividend date of 16th January, 2026.
Key information
3.0%
Dividend yield
0.3%
Buyback Yield
| Total Shareholder Yield | 3.3% |
| Future Dividend Yield | 3.1% |
| Dividend Growth | 11.5% |
| Next dividend pay date | 17 Feb 26 |
| Ex dividend date | 16 Jan 26 |
| Dividend per share | n/a |
| Payout ratio | 494% |
Recent dividend and buyback updates
Recent updates
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
Nov 18
Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer
Nov 08AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear
May 16
AbbVie Q1 Earnings Review: Typically Strong Performance, Aesthetics Aside
Apr 25AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade)
Apr 09AbbVie Vs. Sanofi: Which Is The Better Investment Right Now
Mar 28AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
Mar 13Investors Don't See Light At End Of AbbVie Inc.'s (NYSE:ABBV) Tunnel
Feb 25Why AbbVie Remains A Strong Buy For Long-Term Investors
Feb 23AbbVie: An Undervalued Dividend Aristocrat
Feb 14AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine
Jan 26Upcoming Dividend Payment
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: ABBV's dividends per share have been stable in the past 10 years.
Growing Dividend: ABBV's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| AbbVie Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ABBV) | 3.0% |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 2.2% |
| Analyst forecast (ABBV) (up to 3 years) | 3.1% |
Notable Dividend: ABBV's dividend (3.04%) is higher than the bottom 25% of dividend payers in the US market (1.47%).
High Dividend: ABBV's dividend (3.04%) is low compared to the top 25% of dividend payers in the US market (4.48%).
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (494.2%), ABBV's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (62.1%), ABBV's dividend payments are covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/01 02:43 |
| End of Day Share Price | 2025/11/28 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AbbVie Inc. is covered by 52 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Luisa Hector | Berenberg |
| Evan Seigerman | BMO Capital Markets Equity Research |